Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival
about
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contraMETastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.Prognostic Utility of PET in Prostate Cancer.Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.Current approaches to incorporation of radium-223 in clinical practice.Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
P2860
Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival
description
im Juli 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 27 July 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2014
@uk
name
Quantification of skeletal met ...... sion-free and overall survival
@en
Quantification of skeletal met ...... sion-free and overall survival
@nl
type
label
Quantification of skeletal met ...... sion-free and overall survival
@en
Quantification of skeletal met ...... sion-free and overall survival
@nl
prefLabel
Quantification of skeletal met ...... sion-free and overall survival
@en
Quantification of skeletal met ...... sion-free and overall survival
@nl
P2093
P2860
P50
P356
P1433
P1476
Quantification of skeletal met ...... sion-free and overall survival
@en
P2093
Campbell Tait
Clare Hodgson
David Moore
Jim Growcott
Michael Malone
Thomas Morris
P2860
P304
P356
10.1111/BJU.12717
P577
2014-07-27T00:00:00Z